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Case Presentation
A 17-year-old male was transferred to the New England Medi-
cal Center Hospital (NEMCH) for evaluation of acute renal fail-
ure following a 5-day episode of nausea and vomiting. During a
routine examination 3 months earlier, his blood pressure had
been 98/64 mm Hg and laboratory findings included a hematocrit
of 40% and a white blood cell count of 8700 mm3 with a normal
differential. Urinalysis revealed a specific gravity of 1.010, pH
6.0, and no protein or glucose. The patient received a routine
diphtheria-tetanus vaccination at that time. Two weeks prior to
admission, he returned from a camping trip and complained of
myalgias and a temperature of 102° F for 2 to 3 days. Five days
prior to admission, nausea, vomiting, and diarrhea began. One
day prior to admission, he noted "puffy cheeks" and "poor col-
or," and he went to a local hospital. Laboratory findings there
revealed serum sodium 142 mEq, chloride 103 mEq, potassium
7.8 niEq, and bicarbonate 17 mEq per liter. The blood urea nitro-
gen (BUN) was 190 mg/dl and the serum creatinine was 21.4 mg/
dl. Urinalysis revealed a specific gravity of 1.022, pH 5, 4+ pro-
tein, and 4+ blood. Urine sediment contained 7 to 10 white blood
cells, 10 to 12 red blood cells, and 4 to 6 coarse granular casts per
high-power field. The hematocrit was 20%; anisocytosis and
poikilocytosis were noted on the peripheral smear. The platelet
count was 134,000 mm3. The patient was treated with glucose
and insulin and was immediately transferred.
The past medical history disclosed significant congenital ab-
normalities, including an imperforate anus and a rectourethral
fistula. A colostomy was surgically formed at age 5 days. At 1
year he had an abdominal peroneal "pull-through" operation re-
sulting in nearly normal bowel control. Because of intermittent
enuresis, he was treated with Tofranil® 50 mg orally each eve-
ning.
Physical examination on admission to NEMCH revealed a
pale alert male in no acute distress. His blood pressure was 148/
80 mm Hg, pulse 67, respirations 19. The physical examination
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was unremarkable except for a grade IVVI systolic ejection mur-
mur. His oral pharynx was clear. There was no rash, costoverte-
bral angle tenderness, pitting edema, or lymphadenopathy.
The laboratory findings revealed: serum sodium 139 mEq, po-
tassium 7.5 mEq, chloride 101 mEq, and bicarbonate 19 mEq per
liter. The BUN was 207 mg/dl, and the serum creatinine was 21.9
mg/dl. Urinalysis revealed a specific gravity of 1.010, pH 6, 2+
protein, and 2+ blood. Urine sediment contained 6 to 10 white
blood cells, 6 to 10 red blood cells, and occasional tubular cells
and coarse granular casts per high-power field. There were no
cellular casts. The hematocrit was 20%; white blood cell count
12,300 mm3; and platelet count 384,000 mm3. The reticulocyte
count was 17%. Examination of the peripheral blood smear re-
vealed 3+ anisocytosis, 2+ poikilocytosis, 2+ microcytes, 2+
macrocytes, 2+ schistocytes, and 1 + polychromatophilia. Pro-
thrombin time: patient, 11.5 sec; control, 11.0 sec. Partial
thromboplastin time: patient, 29.0 sec; control 25.0 sec. A sugar-
water test was negative. Autohemolysis was less than 1%.
Plasma haptoglobin was 10 mg/dl (normal 50-200 mg/dl). An anti-
nuclear antibody test was negative. Glucose-6-phosphate dehy-
drogenase and pyruvate kinase tests were normal. The elec-
trocardiogram was remarkable only for peaked T waves.
A percutaneous femoral vein catheter was placed, and the pa-
tient underwent 21/2 hours of hemodialysis against a zero-potas-
sium bath. He received 3 additional dialysis treatments over the
next 4 days. The urine output exceeded 400 cc for the first time
on the fifth hospital day and gradually increased thereafter. The
BUN was 25 mg/dl and the serum creatinine was 1.7 mg/dl at
discharge, approximately 3 weeks after admission. One month
later, the patient was doing well clinically. Random urinalysis
revealed no protein. The hematocrit was 28%, the reticulocyte
count was 2.4%, and the BUN and serum creatinine were nor-
mal.
Discussion
DR. LILIANE MOREL-MAROGER (Maître de Re-
cherche a l'Institut National de Ia Sante et de la
Recherche Médicale, Service du Professeur Richet,
Hôpital Tenon, Paris, France): Although I am a
morphologist being asked to arrive at a diagnosis
without a renal biopsy, I will guess from the history
that this patient had some form of hemolytic-uremic
syndrome. He presented with all the features of
Presentation of the Forum is made possible by grants from Smith
Kline & French Laboratories, Hoechst-Roussel Pharmaceuticals
Inc., CIBA Pharmaceutical Company, GEIGY Pharmaceuticals,
and Boehringer Ingelheim Ltd.
0085-2538/80/0018-0125 $02.00
© 1980 by the International Society of Nephrology
The Nephrologv Forum is designed to relate
the principles of basic science to clinical prob-
lems in nephrology.
Editors
JORDAN J. COHEN
JOHN T. HARRINOTON
JEROME P. KASSIRER
New England Medical Center Hospital
Boston, Massachusetts
126 Nephrology Forum
acute renal failure and some of the findings of mi-
croangiopathic anemia. In the absence of a renal
biopsy, however, it is difficult for me to be specific
about the nature of this patient's disease; never-
theless, I will review briefly the clinical findings and
then consider the possible morphologic counter-
parts of his acute renal failure.
In Dr. Gabriel Richet's group at Hôpital Tenon,
the policy in the renal intensive care unit over the
last 12 years apparently has been quite different
from yours. As a rule, a renal biopsy is performed in
any patient with acute renal failure that is not obvi-
ously due to classic tubular necrosis, that is, in any
patient in whom the cause of renal disease is not
clear. The biopsy is done as soon as possible, pro-
vided no contraindications such as hypertension, a
single kidney, or a coagulation disorder are present.
This policy has allowed us to recognize a variety of
disorders affecting the kidney that otherwise might
have gone undetected [1, 2].
When admitted to the New England Medical Cen-
ter Hospital, this patient had severe acute renal fail-
ure that necessitated hemodialysis. As I mentioned,
he also had some features suggestive of micro-
angiopathic anemia, namely schistocytosis and re-
ticulocytosis. The reticulocyte count was 17%; this
figure is well within the range we observed in a se-
ries of patients with the hemolytic-uremic syn-
drome, all of whom had more than iO reticulocytes
per mm3 [3, 4]. In addition, burr cells and alow hap-
toglobin level were present. Thus, the clinical diag-
nosis of hemolytic-uremic syndrome can be strong-
ly suspected despite some atypical features includ-
ing marked qualitative proteinuria and urinary
casts. Although these findings can occur in any oh-
guric patient, and we have found them in adult pa-
tients with a variety of lesions including tubular ne-
crosis [2], these features are relatively uncommon
in the hemolytic-uremic syndrome. Moreover,
spontaneous recovery of renal function occurred
very rapidly. This course is atypical of the hemo-
lytic-uremic syndrome in adults; recovery usually
requires several weeks. Although the platelet count
was normal when the patient was discharged, the
minimal hematologic abnormalities that did persist
could be interpreted as evidence of an underlying
microangiopathic anemia, perhaps related to a le-
sion of the renal arteries or arterioles. That he was
not hypertensive does not entirely rule out this pos-
sibility [4]. The patient himself noted puffy cheeks,
again an unusual manifestation of the hemolytic-
uremic syndrome in adults. Although this symptom
might suggest an acute nephritic syndrome, the pa-
tient did not have macroscopic hematuria, overt
edema, or hypertension; thus, I do not believe that
he had acute postinfectious glomerulonephritis.
This patient was free of any personal or familial
renal antecedents, and we know that three months
earlier he had had a normal urinalysis. The first sign
of trouble occurred when he returned from a camp-
ing trip complaining of nausea, abdominal pain, di-
arrhea, and fever. Although no medical data were
gathered at that time, we can entertain a few possi-
bilities: he might have had a transient bacterial in-
fection—perhaps with a Gram-negative organism—
or he might have been bitten by an insect or an ani-
mal such as a dog [5]. Also, he might have suffered
from the prodromic period known to occur in the
hemolytic-uremic syndrome in many children [6].
I would like to turn now from this patient to a
broader consideration of this interesting condition.
As Kaplan and Drummond have emphasized, it is
likely that the hemolytic-uremic syndrome can oc-
cur in response to various causative factors [7]. The
exact triggering mechanisms, however, are still un-
known. In young children, in whom the condition
was first recognized, the hemolytic-uremic syn-
drome is a reasonably clear-cut clinicopathologic
entity. In this age group, the syndrome is character-
ized by microangiopathic anemia and acute renal
failure, either with anuria or with an acute nephritic
syndrome. The child usually experiences a pro-
dromic phase, as did the patient who is the subject
of this Forum; the prodrome is characterized by
acute transient gastrointestinal symptoms, respira-
tory symptoms, or generalized malaise. On patho-
logic examination, the renal lesions as first de-
scribed by Gasser suggest cortical necrosis [8]. Ha-
bib et al, however, have described a specific lesion,
which they have named thrombotic micro-
angiopathy [9]. This lesion is characterized by a
thickening of the capillary walls due both to the
deposition of a fluffy, finely fibrillar material and to
a swelling of the endothelium. Sometimes these
changes occur in association with mesangial thick-
ening; in addition, aggregated platelets and dam-
aged erythrocytes tend to be sequestered in the cap-
illary lumina or in the subendothehial space. Various
degrees of intimal and endothehial proliferation, as
well as arteriolar thrombosis can be present, espe-
cially in older children. Several subsequent reports
of the pathology of this condition have appeared [3,
4, 10-14].
In adults, the hemolytic-uremic syndrome is a
much more heterogeneous condition. The clinical
syndrome can occur under various circumstances,
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many of which are listed in Table 1 [4, 15—33]. Be-
tween 1969 and 1977 we observed at the Hôpital Te-
non 31 adult patients with the hemolytic-uremic
syndrome. Our experience with these patients
clearly shows that an early renal biopsy in hemo-
lytic-uremic syndrome can provide useful informa-
tion. All of the 31 patients were hospitalized for
acute renal failure and hemolytic anemia of the mi-
croangiopathic type" [34]. The presumptive diagno-
sis of hemolytic anemia was made when the hema-
tocrit rapidly fell below 30% in the absence of
bleeding and the reticulocyte count was found to be
greater than l0 per mm3. The diagnosis was further
strengthened by the finding of a low serum hap-
toglobin level in all patients in whom it was mea-
sured. Fragmented red cells were present in blood
smears of most patients in whom they were sought.
Fourteen patients had ocular lesions consisting of
soft exudates; one had an inflammatory retinal de-
tachment. Purpura occurred in only 3 patients.
Causative factors possibly responsible for the he-
molytic-uremic syndrome were present in 21 of the
31 patients: previous hypertension existed in 9,
multiple systemic sclerosis in 4, pregnancy in 3,
acute promyelocytic leukemia in one, and pulmo-
nary hypertension in one; 2 used oral contraceptive
pills. Elapsed time between onset of the clinical
syndrome and the diagnosis by renal histology var-
ied from 4 days to 3 months.
On the initial biopsy samples, all 31 patients had
glomerular lesions; 28 patients also had con-
spicuous arterial and arteriolar lesions. The gb-
merular lesions fell into two categories: The first
were identical to the thrombotic microangiopathy
described in young children with this syndrome,
namely, clear fluffy subendothelial deposits, swell-
ing of the endothelium giving the capillary wall a
Table 1. Presumed causative or associated factors in the adult
hemolytic-uremic syndrome
Viruses
Shigellosis
Lipopolysaccharides and septicemias
Microtatobiotes
Dog bite
Snake bite
Drugs (phenylbutazone)
Contraceptive pills
Pregnancy
Radiation
Transplantation
Scieroderma
Renal vascular lesions and/or hypertension
Red cell membrane phospholipid alterations
Platelet lesions
Addison's disease
thickened appearance [35], fibrillar widening of
mesangial areas, intact or fragmented erythrocytes
in the capillary lumina, glomerular thrombosis, and
diffuse glomerular congestion. This combination of
lesions, when severe, markedly reduced the caliber
of the capillary lumina and frequently occluded
them. The second principal lesion consisted of is-
chemic gbomeruli, with thickening and wrinkling of
the glomerular basement membrane, atrophy of the
glomerular tuft with disappearance of most nuclei
and partial loss of structure, and thickening of Bow-
man's capsule [36]. In 5 patients, thrombotic micro-
angiopathy was present alone, whereas both the
thrombotic microangiopathy and the ischemic le-
sions were present in all the others. The proportion
of both types of lesions varied widely from one pa-
tient to the next.
On immunofluorescent examination, no immuno-
globulins except traces of 1gM were detected in the
gbomeruli. Both 1gM and C3 were found in most ar-
terial walls, but this finding does not appear to be
significant. Sizable amounts of fibrinogen were
found in the subendothelial glomerular deposits and
the glomerular thrombi, but stains for fibrin were
consistently negative by light microscopy. Arteri-
olar thrombi also contained fibrinogen, which was
present in the media and sometimes in the thick-
ened intima of a few medium-sized arteries. Some
investigators [37] have reported finding more immu-
nogbobulins than we did, but the difference probably
relates to the stage of the lesions.
in a recent study of 20 adults with the hemolytic-
uremic syndrome, we focused on renal biopsies ob-
tained during the first 30 days after the onset of
acute renal failure [4]. We found that the severity of
the glomerular, tubular, and interstitial lesions did
not differ between the 4 patients who recovered
good renal function and those who did not. Vascu-
lar lesions, however, especially those that could be
attributed to intravascular coagulation, were less
severe in patients who recovered. This finding sug-
gests that changes in small intrarenal arteries are re-
sponsible for the irreversible renal damage (often
leading to cortical necrosis) that occasionally oc-
curs in the hemolytic-uremic syndrome.
Recent studies suggest that the hemolytic-uremic
syndrome in adults might be triggered by an intra-
vascular coagulation that can become superim-
posed on various underlying anomalies (Fig. 1). The
precise pathogenesis of the hemolytic-uremic syn-
drome is still unknown, but it is likely to result from
any event giving rise to intraglomerular coagulation
[38-42]. This assumption is strengthened by the
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Fig. 1. Proposed pat hogenesisfrr the renal lesions characteristic
of hemolytic-uremic syndrome in adults.
multiple circumstances in which this clinical and/or
histologic syndrome has been reported (see Table 1)
and in which the only common denominator is the
presence of some factor inducing intravascular co-
agulation. Unfortunately, no animal model for the
hemolytic-uremic syndrome exists, probably be-
cause no experimental condition has been devised
for producing the kind of glomerular endothelial
damage required for intravascular coagulation at
this site 138, 41].
Evidence for the importance of intravascular co-
agulation in the hemolytic-uremic syndrome is pro-
vided by the combination of microangiopathic
anemia [34, 39], thrombocytopenia, and the pres-
ence of fibrinogen in the glomeruli. These findings
have prompted numerous therapeutic attempts us-
ing heparin or other anticoagulant drugs [42-48]. Al-
though all of the triggering causes of the hemolytic-
uremic syndrome have not been identified, it is now
known that multiple factors exist: (1) Some patients
appear to have a defect of a plasma factor. Upshaw
described a patient who suffered from several acute
episodes of microangiopathic anemia that were re-
versed by administration of normal plasma [49].
This plasma defect was attributed by Remuzzi et al
to the lack of a prostacyclin inhibitor [50]. They
successfully treated patients who had the hemo-
lytic-uremic syndrome with fresh plasma infusion.
Whether these plasma "deficiencies" are acquired
or congenital is unknown [51], but this mechanism
could explain instances in which the syndrome is
familial [52]. (2) Anomalies of circulating blood cells
also might have a causative role in some instances.
Blatter et al reported an abnormally high percentage
of megathrombocytes in three siblings with the he-
molytic-uremic syndrome [53]. In a personal com-
munication, Drummond has suggested that a modi-
fication of the red cell membrane could trigger the
hemolysis. (3) Intravascular coagulation also might
be induced by immunologic factors, perhaps medi-
ated by immune complexes that have been found in
some patients with the hemolytic-uremic syndrome
[54]. A role for immune mechanisms in the hemo-
lytic-uremic syndrome is further supported by the
presence of low levels of complement or of C3-split-
ting activity in several patients [54—57]. In some of
these individuals, evidence for complement activa-
tion persisted after bilateral nephrectomy and trans-
plantation; these findings led Kourilsky et alto pos-
tulate that some patients with the hemolytic-uremic
syndrome have a primary abnormality of their com-
plement system [58]. This defect and possibly oth-
ers also could explain the occurrence of the syn-
drome in families [52] as well as account for some
epidemic forms in which a subtle 'immune defi-
ciency" renders the individuals more susceptible to
the syndrome [59, 60]. (4) It is now established that
the hemolytic-uremic syndrome can be superim-
posed on underlying renal disease; examples in-
clude the hemolytic-uremic syndrome occurring in
patients with scieroderma [61, 62] or primary gb-
merular disease [63]. Whatever the exact mecha-
nism triggering intraglomerular coagulation, a de-
fect probably exists in the local fibrinolytic mecha-
nism of the glomeruli. Experimental observations in
rats indicate that infusion of thrombin leads to ex-
tensive accumulation of fibrinogen thrombi in the
gbomeruli, but these thrombi are cleared from the
glomeruli in one hour [64, 65].
Some investigators have advocated the use of
heparin in the hemolytic-uremic syndrome, espe-
cially if the lesions on renal biopsy appear fresh and
inflammatory and if the glomeruli are filled with fi-
brinogen-related antigens [42-47]. The beneficial ef-
fects of heparin, however, have not been confirmed
[48]. It is difficult to establish the efficacy of any
treatment in the absence of controlled trials when
the natural history of the disease in question is un-
defined [4, 6, 7, 23]. Some patients described in the
literature and some in our series have seemed re-
sponsive to heparin therapy, but we cannot say that
they would not have recovered spontaneously. In
the patient we are discussing today, the renal recov-
ery was clearly spontaneous. The long-term outlook
of patients with the hemolytic-uremic syndrome,
even after apparent recovery, is also in doubt. In
our series, some patients developed hypertension
and severe ocular damage after the hemolytic-ure-
mic syndrome; this complication suggests that vas-
cular damage might be asymptomatic initially and
then progress to cause secondary hypertension.
In my view, the most important point illustrated
by the patient who was presented today is the use-
fulness of a renal biopsy. This patient had no con-
traindication to renal biopsy; the platelet count was
above 100,000 mm3 and he was not hypertensive. Is
Intravascular coagulation
7-
Glomerular endothelial Arterial lesions
lesions
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an early biopsy warranted in "atypical acute renal
failure"? My answer would be an unequivocal yes.
An early renal biopsy is probably the only way to
establish a definite diagnosis rapidly. It is true that
from the clinical history of this patient, we probably
can exclude a minor form of acute glomerulonephri-
tis because he did not have findings typical of the
nephritic syndrome. It is quite possible, however,
that both his acute renal failure and his hemolytic
anemia were independent manifestations of some
other process and that morphologic examination
would have revealed nothing more than acute tubu-
lar necrosis. Dr. Kanfer in our group has observed
three patients with tubular necrosis immediately af-
ter childbirth; these patients all had anemia with
schistocytosis and they were anuric [66]. In addi-
tion to clarifying the diagnosis, an early renal
biopsy often can provide important prognostic in-
formation; the experience in Dr. Richet's depart-
ment is that prognosis differs considerably in pa-
tients with purely tubular renal lesions from that in
patients with microangiopathy. Alternatively, a re-
nal biopsy in this patient might have shown throm-
botic microangiopathy. As I mentioned earlier, the
rapidity with which his renal function recovered is
surprising, as is the persistence of minor hematolog-
ic abnormalities. Nevertheless, if thrombotic micro-
angiopathy had been found, some idea of the prog-
nosis could have been gleaned from the presence or
absence of the severe arteriolar changes I have de-
scribed.
To conclude, I propose two alternative morpho-
logic possibilities: acute tubular necrosis with a
coincidental hematologic disorder, or thrombotic
microangiopathy with mild arterial lesions. If the
first hypothesis is true, this patient's renal lesion is
healed. If the second obtains, hemolytic-uremic
syndrome might recur; we have observed this phe-
nomenon in two patients and another has been de-
scribed in the literature [67]. Finally, this patient
should be monitored carefully both for recurrence
of the syndrome and for the possible development
of hypertension.
Questions and Answers
DR. JORDAN J. COHEN: We are fortunate to have
Dr. Renée Habib with us today. Dr. Habib, you
have contributed much to our understanding of the
hemolytic-uremic syndrome, as acknowledged by
Dr. Morel-Maroger in her numerous references to
your work. I hope you will feel free to participate in
the discussion.
DR. RENÉE HABIB (Directeur de Recherche a
!'I.N.S.E.R.M., Unite 192 de Nephrologie Pedi-
atrique, Hópital Necker —Enfants-Malades, Paris):
Thank you. I would like to comment on Dr. Morel-
Maroger's hypothesis that intravascular coagulation
is the primary event in the hemolytic-uremic syn-
drome. Evidence strongly suggests that this disease
is not a form of disseminated intravascular coagu-
lation [6]. Local intravascular coagulation does
occur, but I believe it is a secondary phenomenon.
My hypothesis is that the primary event, a lesion
of the endothelial cell layer, predominates in the
arteries and arterioles in some instances and in the
glomerular capillaries in others.
DR. JOHN T. HARRLNGTON: Can one produce he-
molytic-uremic syndrome in an experimental ani-
mal by inducing intravascular coagulation?
DR. MOREL-MAROGER: There is no valid experi-
mental model for the hemolytic-uremic syndrome.
As I mentioned earlier, when intraglomerular
thrombi are produced in the rat, they are removed
rapidly by local fibrinolytic activity [65]. Efforts to
produce a model in rabbits have only succeeded in
creating renal cortical necrosis [38].
DR. COHEN: Dr. Herrin, first would you comment
on your experience with the hemolytic-uremic syn-
drome in children? Second, how do you treat these
patients?
DR. JOHN HERRIN (Chief, Pediatric Nephroiogy,
Massachusetts General Hospital, Boston): The
clinical spectrum of hemolytic-uremic syndrome is
wider in the pediatric age group than in adults. In
addition, in childhood there is usually a more clear-
cut prodrome, which often suggests a viral illness
but sometimes indicates one that is bacterial in ori-
gin. Pathologic findings in the hemolytic-uremic
syndrome are not necessarily confined to the blood
and kidney; close review, especially of older chil-
dren, reveals a more generalized syndrome, with
gastrointestinal involvement often quite prominent.
Perforations of the gastrointestinal tract can occur.
Furthermore, considerable variation in clinical fea-
tures can occur at different times, even at the same
hospital. Over the past 8 years, we have treated ap-
proximately 20 children with the hemolytic-uremic
syndrome; the clinical picture seems to vary from
year to year, ranging from relatively mild in one
year to very severe in another.
The efficacy of therapeutic modalities is difficult
to assess in this heterogeneous disorder because it
has such a variable natural history. Assessment is
particularly difficult because aggressive supportive
treatment alone, when undertaken in the active
phase of the illness, reduces the mortality rate dra-
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matically [68, 69]. Thus, claims for the efficacy of
heparin, streptokinase, acetylsalicylic acid, dipy-
ridamole, and other compounds must be compared
with the results of supportive care alone. Currently,
90% to 95% of children with hemolytic-uremic syn-
drome survive with conservative therapy without
anticoagulants [70]. Our most pressing concern is to
find methods for identifying in advance the 5% to
10% of patients in whom spontaneous recovery
does not follow control of fluid and electrolyte bal-
ance and peritoneal dialysis; it is this group in which
experimental treatments need to be evaluated.
DR. HABIB: I agree that we see a wider clinical
spectrum in very young children than we do in
adults. In adults the disease is almost always se-
vere, whereas babies exhibit a mild form of the dis-
ease and have an excellent prognosis. In our experi-
ence, the dividing line is about 2 years of age; the
disease in older children behaves very much like
that in adults. But the real difference in presentation
is not related to age; it is related to the type of renal
involvement. In the near future we will publish a
study conducted over the last 10 years of 70 chil-
dren. In the 52 patients in whom we were able to
obtain kidney specimens, we found 10 patients with
cortical necrosis, 29 with the characteristic features
of glomerular thrombotic microangiopathy, and 13
with predominant arterial involvement and ischem-
ic glomerular changes. Most of the adult cases that
have been reported belong to the last category. In
fact, 10 of the 15 children over 2 years of age in our
series had predominant arterial involvement, and 9
of them developed severe hypertension that neces-
sitated bilateral nephrectomy. Another big dif-
ference in the syndrome between children and
adults is that it is often manifested as a secondary
disorder in adults. In most children, the hemolytic-
uremic syndrome is primary.
DR. MANUEL MARTLNEZ-MALDONADO (Director
of Medical Services, San Juan VA Hospital, San
Juan, Puerto Rico): Is it possible that the primary
disorder is an affliction of the platelets? Let us as-
sume, for example, that a virus infects the platelets
and leads to release of prostacyclin, which in turn
stimulates the glomeruli to synthesize thrombox-
ane. Couldn't that stimulation cause the endothelial
lesion and explain all the pathologic and clinical
manifestations of the disease?
DR. MOREL-MAROGER: I believe that the hemo-
lytic-uremic syndrome is a heterogeneous condition
and that a single causative factor is not likely. Pri-
mary platelet anomalies have been described in mi-
croangiopathic anemia, but I am not aware of any
patients with hemolytic-uremic syndrome in whom
the renal lesion was clearly caused by a platelet dis-
order. Many diseases in which thrombotic micro-
angiopathy is not present exhibit platelet activation.
Also I know of no satisfactory explanation for the
accumulation of fibrin in the glomeruli. As I men-
tioned, if one induces intraglomerular coagulation
experimentally, as Dr. J. D. Sraer did in Hôpital
Tenon [65], the local fibrinolytic activity of the
glomeruli removes capillary thrombi within one
hour.
DR. KENNETH SHAPIRO (Renal Fellow,
NEMCH): Do you believe prostaglandins play any
role in the pathogenesis of this disorder?
DR. MOREL-MAROGER: The situation is so com-
plicated that it is difficult to know. The only infor-
mation relevant to your question is that of Remuzzi
et al, who suggested that hemolytic-uremic syn-
drome is related to the absence of a plasma factor
that normally stimulates prostaglandin production
[50].
DR. JEROME P. KASSIRER: Given the clinical pre-
sentation of this patient and his remarkable re-
sponse to supportive therapy alone, what do you
think the biopsy might have shown?
DR. MOREL-MAROGER: The clinical presentation
and the rapid recovery do not allow a precise classi-
fication of this patient; of the two possibilities I sug-
gested, acute tubular necrosis would be the more
likely diagnosis; thrombotic microangiopathy would
be my second guess.
DR. HABIB: This question reminds me of the
good old days" and how we used to discuss pa-
tients who had the nephrotic syndrome. We all
know that lipoid nephrosis is the most frequent
cause of nephrotic syndrome in children, but we
now know that several glomerular diseases can
mimic lipoid nephrosis. The situation with hemo-
lytic-uremic syndrome is analogous. Even though
thrombotic microangiopathy —either with pre-
dominant glomerular involvement or with pre-
dominant arterial involvement—is the most fre-
quent cause of the hemolytic-uremic syndrome,
other conditions can mimic it. I know of many pa-
tients who appeared to have hemolytic-uremic syn-
drome clinically but who, at biopsy, did not show
lesions consistent with either glomerular or vascu-
lar thrombotic microangiopathy. Most of the pa-
tients recovered very rapidly. The problem is even
more complicated in adults because of the high in-
cidence of secondary hemolytic-uremic syndrome.
DR. KASSIRER: You alluded to the risk of renal
biopsy in patients with this condition. Can you elab-
orate on those risks in your series?
DR. MOREL-MAROGER: In our series of 20
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biopsies, 4 were complicated by retroperitoneal he-
matomas [4]. Thus, the risk associated with biopsy
in patients with the hemolytic-uremic syndrome
might be higher than in other groups of patients —
those with nephrotic syndrome, for example. In the
absence of a coagulation disorder or hypertension,
however, I think the risk of biopsy is worth taking.
DR. COHEN: Dr. Habib, what do you regard as
the indications for renal biopsy in children and
adults suspected of having hemolytic-uremic syn-
drome? Does the biopsy provide therapeutic guid-
ance or is it useful simply for estimating the progno-
sis?
DR. HABIB: I consider renal biopsy useful for es-
timating the prognosis. The procedure not only al-
lows one to distinguish among the three pathologic
patterns observed, that is, cortical necrosis, throm-
botic microangiopathy with predominant glomeru-
lar involvement, and thrombotic microangiopathy
with predominant vascular involvement, but in the
glomerular form of the disease, renal biopsy also
can provide an estimate of the percentage of glome-
ruli affected. In our experience, most of the patients
who eventually developed residual renal functional
impairment had more than 50% of their glomeruli
affected on the initial biopsy. From a study per-
formed in our laboratory, we know that the gb-
merular damage is irreversible; in subsequent
biopsies performed one year after onset of the syn-
drome, the percentage of sclerotic glomeruli corre-
sponded exactly to the percentage of affected
gbomeruli observed on the initial biopsy [71]. Be-
cause we are dealing with a syndrome, a renal
biopsy also might be helpful in establishing the cor-
rect diagnosis. The patient presented today well il-
lustrates the problems raised in differential diagno-
sis when a renal biopsy has not been performed.
DR. JOHN DONOHOE (Consultant Nephrologist,
Mater Misericordiae Hospital, Dublin, Ireland):
Would you comment on the possible efficacy of
converting enzyme inhibitor in the treatment of this
condition? It is claimed that converting enzyme in-
hibitor is very helpful in so-called scleroderma
crisis, in which the vascular lesions are like those
that you described in the hemolytic-uremic syn-
drome.
DR. MOREL-MAROGER: Let me first comment on
the renal lesions in scleroderma. The glomerular le-
sions are exclusively ischemic. The presence of
fibrinogen in the glomeruli does, of course, support
the suggestion that local coagulation occurs, but I
do not believe that these glomerular lesions are ever
of the thrombotic microangiopathic type. I admit
that some patients with scieroderma crisis recover
considerable renal function with treatment [61, 62].
Although no studies have been reported of serial
biopsies documenting the disappearance of arterial
proliferation, this is probably what happens at the
local level. Serum from patients with scieroderma
recently has been shown to contain a factor that is
toxic for endothelial cells [72]. I am not aware of an
attempt to use converting enzyme inhibitor in the
treatment of hemolytic-uremic syndrome unrelated
to scieroderma, but it would be an interesting study,
especially in adults with extensive vascular lesions.
DR. BRUCE CHAN (Renal Division, Rhode Island
Hospital, Providence, Rhode Island): Would you
add acute albograft rejection to the list of causes of
adult hemolytic-uremic syndrome? If so, it is inter-
esting to note that heparin therapy in the treatment
of allograft rejection has been pretty much aban-
doned.
DR. MOREL-MAROGER: Yes, I would include re-
jection—at least from the morphologic point of
view—as a cause of thrombotic microangiopathy in
adults. I agree that heparin is useless in such cir-
cumstances but I cannot imagine that any therapy
would have been valuable in the few patients I have
seen. These were individuals in whom the most
prominent feature was the combination of arterial
lesions—very much like those of scieroderma—and
ischemic glomeruli, with a few loops enlarged by
fibrillar deposits. These lesions were not reversible.
DR. KASSIRER: Dr. Habib, do you think heparin
has any value in the treatment of the hemolytic-ure-
mic syndrome?
DR. HABIB: Our data and those of others [46] sug-
gest that it has no value in children. We found in a
retrospective study that the recovery rate was even
higher in the nontreated group as compared to the
treated group (Table 2). These results do not mean
much, however, because of the wide spectrum of
renal involvement observed. Moreover, it is likely
that we tended to treat those patients who were
more severely affected. There are no controlled
studies but even if such a study were done, I think it
would be very difficult to interpret.
DR. COHEN: The pathologic lesions you de-
scribed in patients with hemolytic-uremic syndrome
are reminiscent of some of the lesions occurring in
thrombotic thrombocytopenic purpura. Do you
think any relationship exists between these two
conditions?
DR. HABIB: The hemolytic-uremic syndrome and
thrombotic thrombocytopenic purpura have three
common features: microangiopathic hemolytic
anemia, thrombocytopenia, and arteriolar throm-
bosis. We arbitrarily make a diagnosis of hemolytic-
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Table 2. Primary hemolytic-uremic syndrome
Outcome
No treatment Heparin
TotalInfants ChildrenInfants 0Children
N= 20 N=5 N= 35 N= 10 N=70
Recovery 13 2 21 2 38
Proteinuria 2 0 2 0 4
BP1 1 1 3 0 5
GFR1'Oj, 1 0 4 0 5
GFR+BP1' 0 1 1 0 2
ESRFC+BPI 3 1 4 8 16
BP denotes blood pressure
b GFR denotes glomerular filtration rate
ESRF denotes end-stage renal failure
uremic syndrome when renal manifestations pre-
dominate; in a small percentage, central nervous
system involvement is also evident. Conversely, we
diagnose thrombotic thrombocytopenic purpura
when CNS involvement predominates; renal dis-
ease in these instances is mild or absent. Since we
do not know the cause of either condition, two pos-
sible explanations could account for the observed
overlap: (1) hemolytic-uremic syndrome and throm-
botic thrombocytopenic purpura could represent
variants of the same disease process, differing only
in localization of the arteriolar changes or, (2) he-
molytic-uremic syndrome and thrombotic thrombo-
cytopenic purpura could be two completely dif-
ferent diseases that coincidentally have three com-
mon features, two of which (microangiopathic
hemolytic anemia and thrombocytopenia) are likely
the consequence of the third one, arteriolar throm-
bosis.
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